Supreme Court sides with Teva in MS drug patent dispute

The U.S. Supreme Court reversed a lower court ruling that had invalidated a patent held by Teva Pharmaceuticals for its multiple sclerosis drug Copaxone. Teva (NYSE: TEVA) has spent several years in court attempting to fend off generic competition for Copaxone, which generates annual sales of about $4 billion for the company. The company is based in Israel and has its U.S. headquarters in North Wales, Pa. Copaxone is approved for use in reducing the frequency of relapses in patients with the relapsing…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news